Equities

Ibio Inc

Ibio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.91
  • Today's Change0.01 / 0.53%
  • Shares traded10.67k
  • 1 Year change-71.18%
  • Beta-3.4120
Data delayed at least 15 minutes, as of Sep 20 2024 19:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Jun 30 2023202320222021
ASSETS
Cash And Short Term Investments4.303497
Total Receivables, Net0.206.105.53
Total Inventory--3.900.03
Prepaid expenses0.661.552.07
Other current assets, total21----
Total current assets2645105
Property, plant & equipment, net7.554235
Goodwill, net------
Intangibles, net5.394.850.95
Long term investments------
Note receivable - long term1.711.636.66
Other long term assets0.050.030.02
Total assets4199147
LIABILITIES
Accounts payable1.854.262.25
Accrued expenses4.423.873.00
Notes payable/short-term debt1300.60
Current portion long-term debt/capital leases0.43220.37
Other current liabilities, total1.940.100.42
Total current liabilities22306.65
Total long term debt0.590.0332
Total debt142233
Deferred income tax------
Minority interest--0(0.02)
Other liabilities, total3.655.46--
Total liabilities263638
SHAREHOLDERS EQUITY
Common stock0.020.010.22
Additional paid-in capital304288282
Retained earnings (accumulated deficit)(289)(224)(174)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0(0.21)(0.06)
Total equity1563109
Total liabilities & shareholders' equity4199147
Total common shares outstanding1.020.440.44
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.